International perspectives on suboptimal patient-reported outcome trial design and reporting in cancer clinical trials: A qualitative study by Retzer, A. et al.
Cancer Medicine. 2021;00:1–13.    | 1wileyonlinelibrary.com/journal/cam4
Received: 26 April 2021 | Accepted: 4 June 2021
DOI: 10.1002/cam4.4111  
O R I G I N A L  R E S E A R C H
International perspectives on suboptimal patient- reported 
outcome trial design and reporting in cancer clinical trials: 
A qualitative study
Ameeta Retzer1,2  |   Melanie Calvert1,2,3,4 |   Khaled Ahmed1 |   Thomas Keeley1,5 |   
Jo Armes6,7,8 |   Julia M. Brown9 |   Lynn Calman6,10 |   Anna Gavin6,11 |   Adam W. Glaser6,12 |   
Diana M. Greenfield6,13 |   Anne Lanceley6,14 |   Rachel M. Taylor6,15  |   Galina Velikova12 |   
Michael Brundage16 |   Fabio Efficace17  |    Rebecca Mercieca- Bebber18,19  |    
Madeleine T. King18 |   Derek Kyte1,4,6,20
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1Centre for Patient- Reported Outcomes 
Research, Institute of Applied Health 
Research, University of Birmingham, 
Birmingham, UK
2NIHR ARC West Midlands, London, UK
3Birmingham Health Partners Centre 
for Regulatory Science and Innovation, 
University of Birmingham, Birmingham, 
UK
4NIHR Birmingham Biomedical Research 
Centre and NIHR Surgical Reconstruction 
and Microbiology Research Centre, 
University Hospitals Birmingham NHS 
Foundation Trust and University of 
Birmingham, Birmingham, UK
5GlaxoSmithKline (formerly of CPROR, 
University of Birmingham, Birmingham, 
UK
6UK National Cancer Research Institute 
(NCRI) Psychosocial Oncology 
and Survivorship CSG Subgroup: 
Understanding and Measuring the 
Consequences of Cancer and its 
Treatment, London, UK
7School of Health Sciences, University of 
Surrey, Guildford, UK
8NIHR ARC Kent, London, UK
9Clinical Trials Research Unit, University 
of Leeds, Leeds, UK
Abstract
Purpose: Evidence suggests that the patient- reported outcome (PRO) content of 
cancer trial protocols is frequently inadequate and non- reporting of PRO findings is 
widespread. This qualitative study examined the factors influencing suboptimal PRO 
protocol content, implementation, and reporting, and use of PRO data during clinical 
interactions.
Methods: Semi- structured interviews were conducted with four stakeholder groups: 
(1) trialists and chief investigators; (2) people with lived experience of cancer; (3) 
international experts in PRO cancer trial design; (4) journal editors, funding panelists, 
and regulatory agencies. Data were analyzed using directed thematic analysis with an 
iterative coding frame.
Results: Forty- four interviews were undertaken. Several factors were identified that 
could influenced effective integration of PROs into trials and subsequent findings. 
Participants described (1) late inclusion of PROs in trial design; (2) PROs being con-
sidered a lower priority outcome compared to survival; (3) trialists’ reluctance to col-
lect or report PROs due to participant burden, missing data, and perceived reticence 
of journals to publish; (4) lack of staff training. Strategies to address these included 
training research personnel and improved communication with site staff and patients 
regarding the value of PROs. Examples of good practice were identified.
Conclusion: Misconceptions relating to PRO methodology and its use may under-
mine their planning, collection, and reporting. There is a role for funding, regulatory, 
methodological, and journalistic institutions to address perceptions around the value 
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of PROs, their position within the trial outcomes hierarchy, that PRO training and 
guidance is available, signposted, and readily accessible, with accompanying meas-
ures to ensure compliance with international best practice guidelines.
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1 |  INTRODUCTION
Patient- reported outcomes (PROs) enable the assessment of 
cancer, its impact, and treatment, from the patient's perspec-
tive, and are collected using validated self- reported question-
naires. PROs provide valuable information, including data 
on physical symptoms, treatment toxicities, psychosocial 
problems, global health- related quality of life, to assess treat-
ment effectiveness, and tolerability.1,2
Patient- reported outcome data support informed decision- 
making by patients from diagnosis and throughout treatment.2 
Its value has been recognized by key stakeholders including 
clinicians, funders, regulators, and policy- makers.3– 5 However, 
the growing literature suggests that the quality of PRO data may 
   | 3RETZER ET al.
be compromised6 through the omission of PRO- related content 
in trial protocols.7,8 Moreover, PRO data are often poorly re-
ported9– 11 or not included in trial publications.12 Despite this 
evidence, a substantial, and growing, number of randomized 
controlled trials (RCTs) across all cancer types now include 
PROs as primary and/or secondary endpoints.13,14 Poor PRO 
protocol content and subsequent poor outcome reporting reduce 
the extent to which PRO results reach and inform clinical inter-
actions and decision making, while simultaneously devaluing 
the contribution of trial participants providing this information. 
Qualitative methods have provided important insights into the 
challenges when administering PROs in trials.6 To date, there is 
limited qualitative research exploring the factors affecting PRO 
trial design, data collection and reporting, or patients’ and clini-
cians’ access to PRO data to inform decision making.
The Evaluation of Patient- Reported Outcome Protocol 
Content and Reporting in UK Cancer Clinical Trials (EPiC) 
study used mixed methods to investigate PRO protocol content 
and reporting in a cohort of international cancer clinical trials. 
Phase I highlighted inadequate PRO protocol components, 
widespread non- reporting of PRO trial results, and consider-
able delay and poor standards of reporting where PRO data 
were published.8 More than one- third of the trials, involving 
49,568 participants, failed to publish their PRO findings.
The current paper reports Phase II of the project: a qual-
itative study involving key stakeholders. Our aim was to ex-
amine and describe perceptions of the factors influencing 
suboptimal PRO protocol content, implementation, and re-
porting, including barriers, solutions, and examples of good 
practice.
2 |  METHODS
The study was completed according to the published proto-
col,15 conducting semi- structured face- to- face, and telephone 
interviews between May 2017 and January 2018. The study 
was approved by the University of Birmingham Ethics 
Committee (Ref: ERN_17- 0085).
2.1 | Recruitment
Purposive sampling was used to recruit participants from 
four stakeholder groups: (1) trialists and chief investiga-
tors with experience of cancer trials collecting a PRO as a 
primary or secondary outcome; (2) individuals with lived 
experience of cancer; (3) international experts in PRO can-
cer trial design, including members of international cancer 
and quality of life research organizations, national advisory 
bodies and industry; and (4) journal editors, funding pan-
elists, and regulatory agency representatives (Appendix 
S1). Approaches were via email, either directly, where 
contact details were available in the public sphere, or via the 
center from which they were identified where appropriate. 
Recruitment continued on a rolling basis until data satura-
tion was reached. Eligible individuals were provided with a 
brief outline of the study and those interested in participat-
ing were invited to take part in an interview. Participants 
completed and returned a consent form prior to the interview 
or gave verbal recorded consent.
2.2 | Data collection
All interviews were conducted by a qualitative researcher 
(AR). The interviews were digitally audio- recorded and pro-
fessionally transcribed verbatim. A preliminary topic guide 
was formulated in advance of the interviews informed by 
the research aims, which were iteratively refined to explore 
emerging themes. Additional prompts were developed for 
each participant group as required (Appendix S2).
2.3 | Analysis
Transcripts were analyzed by AR using directed analysis.16 
Findings from previous qualitative and review work, cou-
pled with insights into Phase I of the project, were used to 
develop an initial coding framework. A flexible and itera-
tive approach was used to continually develop and refine the 
coding frame, allowing for the emergence of novel themes. 
Additional codes were developed and included as the analy-
sis progressed and the framework modified accordingly.17 
Transcripts were coded line by line and as the coding frame 
evolved, transcripts were recoded to ensure new themes were 
captured. The coding frame and sample codes were checked 
by DK and MC. Disagreements were resolved through dis-
cussion.18 NVivo 1119 was used for data management and to 
facilitate analysis.
3 |  RESULTS
The interviews lasted for 30– 60  minutes. For recruitment, 
participants were assigned to one of the four pre- defined 
stakeholder groups (trialists and chief investigators; those 
with lived experience of cancer; international experts in 
PRO design; and journal editors, funding panelists, regula-
tory agency representatives). However, several participants 
identified with or had features and experiences that resonated 
with more than one stakeholder group (Table 1).
Interviewees highlighted several barriers and facilitators 
to optimal PRO practice relating to study inception, PRO col-
lection, analyses, data publication, and training and guidance 
(Table 2).
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3.1 | Study inception
During study inception, interviewees reported that PROs 
were often included in discussions at a late stage; or added as 
an “afterthought” to meet funding requirements for example, 
and were considered to be of lower importance in the hier-
archy of trial outcomes. The relevance and priority of PRO 
endpoints in trial design were considered dependent upon the 
clinical characteristics of the cancer type and the nature of 
the intervention. Participants described how, where interven-
tions were intended to prolong life, survival would be a key 
outcome, and PRO data may be of lesser importance to the 
research question. In cases where a range of curative inter-
ventions was available or in a palliative setting, PRO data 
had greater prominence. Other respondents commented on 
difficulties associated with selecting appropriate PROs in tri-
als and perceived reluctance by some trial investigators to 
include PROs owing to concerns regarding their subjectivity 
or cost. Recommendations to address these issues included: 
the need to formulate a clear PRO rationale early in the trial 
design process which incorporated the patient perspective; 
identifying specific PRO aims and objectives; and ensuring 
involvement of PRO expertise during protocol development. 
Participants described how advances in cancer treatment 
supported more curative options, development of less toxic 
treatments, and greater awareness of the effects of living with 
consequences of radical interventions, leading to a growing 
awareness of PRO data and its place in cancer trials and clini-
cal practice.
3.2 | PRO collection and analyses
Identified barriers centered around: perceived lack of stand-
ardized PRO administration compared to more “objective” 
clinical trial outcomes; concern around participant and staff 
burden associated with PRO completion; and a lack of com-
munication with data collection staff regarding the impor-
tance of PRO data to the trial. Missing data were considered 
to be a significant challenge for analyses and concluding 
data. Subsequently, there was a view that the volume of miss-
ing data and its perceived poor quality could contribute to 
T A B L E  1  Qualitative study participant characteristics
Interview group (total) (n)
Country of 
employment (n) Additional areas of expertize/experience (n)
Trialists and Chief Investigators 10 UK 10 Research
Clinical














































































Abbreviations: PRO, patient- reported outcome; UK, United Kingdom; USA, United States of America.
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T A B L E  2  Study phases and themes
Study phase and themes Example quote and source identifier and primary stakeholder group
1. Study inception
Barriers Perceived pressure to 
include PRO
Generally, people tend to pick reasonable measures, reasonable, in cancer trials they do anyway, 
not always, I guess, but I think they are shoehorned in because everyone thinks they should 
fit in HTA type trials, they should be measuring the quality of life [013, Trialist/Chief 
Investigator]
PRO included at a late 
stage
I have been contacted by lots of oncologists who say, “We're doing this trial but we thought we 
ought to tack on this questionnaire or that questionnaire. What do you think?” But it is been an 
afterthought and the rest of the protocol is really quite clearly established but they just want to 
add something a little bit extra but it is not the primary focus. I think that's a problem because 
until patient reported outcomes does become a primary focus for oncology research, then it 
won't get the attention it needs [020, Trialist/Chief Investigator]
Skepticism about PRO Maybe there is some reluctance by some to include them in that they could be considered far too 
subjective, I mean one particular study, we got involved in, there was a lot of debate about 
the use of some patient- reported outcomes and that some critics were saying they are far too 
subjective and that having objective measures of mobility, would be far more useful [015, 
Trialist/Chief Investigator]
Focus on survival Oncology trials center on reduction in patients who are sick, it is about the reduction in survival. 
Patients are not necessarily expected to get much better. It is about reducing the time for 
progression or death. It is because, what is distinctive about oncology, especially in later or 
advanced cancer, it is about longevity and that is what ranks … It is not about well- being, 
functioning, symptomatology, as much as it is about, of course, safety and tolerability are very 
important, that is first and foremost. But when it comes to the efficacy side, it is about survival, 
because of the nature of the disease … what is said to be the most meaningful outcome is those 
time to event outcomes. That is what the experts and other stakeholders say. [029, International 
Expert]
Position of PRO in 
outcome hierarchy
They are usually always sub- protocols; they are not built into the main trial design itself. Because 
the trials are perceived to be so burdensome anyway, that because if you think back to the 
importance in people's minds, it's kind of “the extra little bit,” it is the bit that usually gets cut 
first [043, Trialist/Chief Investigator]
Data required for drug 
approval
In Oncology it typically has not been the case that a drug is approved for Patient- Reported 
Outcomes. Its progression- free survival, overall survival, event- free survival, some type of 
“time to event” that the weight of the evidence falls on. If the Patient- Reported Outcomes 
are reported typically, it serves to supplement and complement. It is not the main outcome of 
interest. [029, International Expert]
Facilitators Formulating clear PRO 
rationale
One of the real key components is a company understanding early in the development program 
why they are going to collect the data and if they are going to collect it, and this really impacts 
the overall data quality that you see later on. If you have not decided earlier, the company or 
drug developer, that you are going to collect PRO and then you only decide later on in the 
development program when you realize that maybe a payer or someone else might ask for that 
data, usually the quality of the data, the hypothesis- generating information and methodology 
is done quite poorly and it is quite difficult to conclude from that data [006, Trialist/Chief 
Investigator]
PRO expertise in protocol 
development
[The PRO advisory group] make recommendations and will sometimes provide some sample 
packs … We do try to get as much of that sort of stuff into the protocol as we can, so that it 
is written in stone as … part of the protocol and any deviation from that is, a deviation to the 
protocol … administration processes, that are too detailed for the protocol might go into a site 
training document or an appendix that is used as instructional material or a checklist for the 
site [010, International Expert]
Inclusion of patient 
perspective
Often the issues that researchers think are important to get out there, are not important to the 
patients. They are more interested in … quality of life measures that sometimes the researchers 
do not put such great store on. They are more bothered in whatever the primary end point was 
and it is very rare for a primary end point to be a quality of life. It is usually progression- free 
survival or overall survival [033, Lived Experience]
(Continues)
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Study phase and themes Example quote and source identifier and primary stakeholder group
New focus on gentler 
treatments
The treatment has advanced to a point where is not just a matter of, can we keep you alive, but, 
can we keep you alive and comfortable, can we improve your survival and improve your 
symptoms, then it starts becoming more important to actually be able to assess the symptoms 
as opposed to when we have drugs that just, universally made people feel God awful. [010, 
International Expert]
Quality of survival I’ve had male patients who now say they wish they hadn't had radical treatments for prostate 
cancer, because of the, you know, what it's left them with, incontinence, impotence. Breast 
cancer patients, years on who have got lymphedema and can't lift their arms up and had 
debilitating things like that or weight gain from steroids. [033, Lived Experience]
Identifying specific PRO 
aims
We listed, effectively, the areas that we wanted to cover. That was urinary symptoms, sexual 
function symptoms, bowel symptoms, and then generic aspects of quality of life, including 
anxiety and depression. Once we listed those key items, we then looked for questionnaires 
[028, Trialist/Chief Investigator]
2. PRO collection
Barriers Selection of PRO 
instruments
The metrics may not be as well established as say, as in cardiac output like that in the randomized 
trial so the metrics may not be as well established, there may be less agreement about how to 
measure things there might be more subjectivity and that can be harder to operationalize, even 
administration may be somewhat looser or less rigorous compared to some more biological 
outcomes that can be standardized and where timing can be adhered to more so I think just 
describing the outcomes might be a bit more challenging, the fact that the outcomes may be 
less well- established, it can be a challenge sometimes [004, Journal Editor/Funder/Regulator]
Balancing participant 
burden and trial aims
There would also be something around the burden. A lot of [ethics committee members] look 
at the burden on the participant, if they are being asked to fill in or complete too many 
questionnaires [041, Journal Editor/Funder/Regulator]
Site staff capacity We are always conscious that nurses and doctors never have enough time to do anything at all. So 
actually many of us feel guilty about the amount of time we are spending talking with doctors 
and nurses, even if it is answering the questions on a survey. I have done this. I have been sitting 
on the ward filling out my survey and someone on the bed opposite started to throw up and I 
just thought, “My nurse should really be going and attending to them. Their needs are more 
important. Come back to me.” And actually, I cannot even remember whether we finished the 
survey or not but that is the hard reality of frontline work [007, Lived Experience]
Expense associated with 
PRO
The pain for this condition subsides in 4 days, so we proposed to develop a diary and they won't 
buy it. They are going with just this one [questionnaire, once a] month … Because they do not 
trust us to do the development. It is too costly. It is going to take up too much time and after 
all, it is just another end point [001, International Expert]
Signaling of PRO 
importance by trialists
If it is not much in the protocol, people do not necessarily think it is that important, right? They 
pay attention to what they are reading and … the more word count … the more explanation 
and the more obvious it is considered important and people sometimes just do not see or see 
the value of what is hardly listed [008, International Expert]
Facilitators Monitoring missing data In the trial … we had to find, a priori, how we would deal with missing data. We also made a very 
substantial effort, at the time the trial was ongoing, not to accept the PRO back from patients 
until they had completed it and we chased patients quite hard when they did not complete it. So 
actually, the amount of missing data was very small [020, Trialist/Chief Investigator]
Buy- in from trial staff If you have it in protocol and you are ready to do this, then you have to convince the people who 
are collecting the patients for you, that it is also important to have this data, to have these 
questionnaires filled out. That is another really problematic hurdle … because patients are 
willing to do this. But it is mainly the personnel and the daily business, that you are too busy to 
do all these things and to discuss this with the patients. You need nurses, you need facilitation 
for people to help you in collecting these data. And that is important. And also to keep up the 
compliance over time. And that is, I think the second hurdle because missing data is one of the 
main issues which is going to, well, to negatively affect the impact of the PRO measures in a 
clinical trial [023, International Expert]
T A B L E  2  (Continued)
(Continues)
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Study phase and themes Example quote and source identifier and primary stakeholder group
Engaging trial participants There has to be some responsibility obviously on the patient, it has to be a shared task so improved 
tech partnership working is what is so important that the patient feels a part of the team and 
actually your data is incredibly valuable to us because it will inform research and clinical 
practice you know as an ongoing issue and it may be years down the line before you may see the 
benefit but you will be contributing to this so you are part of our team [009, Lived Experience]
Use of innovative PRO 
delivery
We have the technology to do all sorts of interesting things in real- time, the reporting and 
recording of data… So I have become more and more interested, PROs and actually what they 
could be rather than what they are [007, Lived Experience]
3. Analyses
Barriers Planning analyses Which are the key items to look at? Because a major problem, when you use lots of different 
questionnaires that cover the same issue, is which one do you count on? … I think it is another 
problem with patient- reported outcomes that you have these issues to deal with; the key items 
that everybody wants to know about or the key questionnaires and then there is a whole raft 
of other things that you have collected. It is not entirely clear how you deal with all that [028, 
Trialist/Chief Investigator]
Team pressures I think part of the problem, particularly with investigator- sponsored studies where you have 
limited resources, even if you have infinite amounts of money, you still have limited resources 
and clearly, the focus is to get the most important data out there as quickly as possible because 
we want to make progress as quickly as possible. So, the Overall Survival data are the things 
you want to get clean, tidy, in, analyzed and presented first and so often, you end up saying, 
“Actually, we're going to focus on that and we're not going to bring in the Quality of Life data” 
or “We're not going to clean those up as a priority.” [018, Trialist/Chief Investigator]
Missing data In one of my studies, a randomized phase II/III we had substantial problems with missing second, 
third, and follow- up reports and then we ended up going from the outset of 80% to below 40% 
in the follow- up and it was nearly impossible to draw any conclusions. [040, Journal Editor/
Funder/Regulator]
Facilitator Handling missing data I think it was discussed with the statisticians … it was probably stated in the protocol how 
we would [manage missing data]. Again, I think to have an a priori approach to what you 
are going to do may help minimize bias when you do report the data [020, Trialist/Chief 
Investigator]
4. Data publication
Barriers Results of other outcomes Very often, when … the trial is not positive, often the Quality of Life data never sees the light of 
day. That is a shame, although I guess it is probably not going to be hugely important because 
if your primary end point is negative, you are probably not going to change practice. It is 
unlikely that you would change practice based on a secondary end point based on patient- 
reported outcomes. I think it is often just expediency. [018, Trialist/Chief Investigator]
Quality of PRO data The … trial group decided not to publish it at all because you lose your reputation when you 
publish bad data so this is something that you usually should not do and also not try to publish 
it in a bad journal, so putting bad data into a bad journal I think is a bad idea. [040, Journal 
Editor/Funder/Regulator]
Selective reporting I think that it may be a rush to statistically significant results, investigators may feel that, “oh, 
this Patient- Reported Outcome is not statistically significant. It may dampen our ability to 
seek additional funding. It may dampen the perceived effectiveness of the intervention.” [031, 
Journal Editor/Funder/Regulator]
Ranking of PRO among 
outcomes
If the PRO were only an exploratory end point within the protocol sometimes they are not even 
mentioned so they might have been mentioned as, “These were end points,” but then you do 
not actually find any of the results or data actually in the publication at all. [006, Trialist/Chief 
Investigator]
Perceived interest in PRO 
findings
If you look at any of the main clinical trial report articles there might be a small paragraph on 
the quality of life outcomes regardless of whether they are really good or just no difference 
between the treatments. Mainly because the interest in both is on survival, progression- free 
survival, response rate, things of that nature which, and toxicity which seems to take more 
precedence. [005, International Expert]
T A B L E  2  (Continued)
(Continues)
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Study phase and themes Example quote and source identifier and primary stakeholder group
Perceived disinterest from 
high- impact journals
If survival's not there … the “harder outcomes” are not there in your paper, you do struggle. We 
start when we try to send papers for publications as high an impact factor as we can go but 
we usually know that we are going to get rejected. We get rejected by Lancet Oncology, for 
example. It is a classic. You just get a little pat on the head but, “Oh, send this to a nursing 
journal.” British Journal of Cancer, some of the big names in the cancer field do not want to 
publish this sort of work so we work our way down the list. [021, Trialist/Chief Investigator]
PRO data in secondary 
papers
As a secondary publication from a trial, unless it showed something really novel or really 
dramatic, it is unlikely and you do not really see Quality of Life data, patient- reported 
outcomes, secondary measures as secondary publications being published in high- impact 
journals. [018, Trialist/Chief Investigator]
Journal constraints The biggest problem here is that in 95% of the Oncology trials, Quality of Life is a supporting end 
point; so it is a secondary end point. That is a big barrier because when you want to publish the 
article, often if it is a secondary end point and there is nothing in there, then it might just end 
up being one paragraph or two paragraph          s with a table in the journal … And so, we have 
faced the challenge before where journals say, “We want primary end point as much as we can 
and then we want you to publish a secondary end point but you only have 2,500 words,” That 
is extremely difficult. [002, International Expert]
Facilitators Presence of PRO 
publication plan
We have always had an analysis plan [for the PRO] and a dissemination plan for how we would 
proceed, how we would analyze the data, how we would publish the data, how we would 
divide the data up, and what sort of papers we would write. [021, Trialist/Chief Investigator]
Accountability to 
stakeholders
The other thing … is about encouraging patient and public involvement in the clinical trials. You 
do that from the very beginning, in terms of developing what the patient- reported outcome 
measures are … then those people should be their conscience and should be saying, “Where 
are the results of this particular outcome measure that we worked with you on?” It becomes 
much more difficult, I think, for them to hide things if they have got a working group of 
people, or Working Advisors on the Steering Group, and to start backing out and not reporting 
things. [041, Trialist/Chief Investigator]
Supplementary information If you are collecting data in PRO or you are collecting data in any point, end point, you know, 
there should always be space either in the article or as supplementary information, you know, 
if there was not space to actually include the data or at least a summary of the data in the 
publication. [006, Trialist/Chief Investigator]
Publication based on merit If you write a good paper and you pitch it at the right journal, there is no reason why it should not 
get published, but it depends on how you write it and you have to put it in the right, you have 
to pitch it appropriately and you have to reflect the journal. [013, Trialist/Chief Investigator]
Publishing in the main 
paper
It is detrimental to publish it separately because often it gets published separately, … months later; 
we have done a study where we looked at the difference in publication times and it was like, 
on average, 18 months later or something, and it is on average, in a [low] impact factor journal, 
much less than the primary outcomes and so I think the chances there are that the Clinicians 
reading it and using that data are not high, so even though people want to publish lots of 
papers, I think it would be better to say to them, publish the PRO results in the main trial paper 
and force them to write them succinctly. [013, Trialist/Chief Investigator]
Demand for PRO data Well there is actually a big hype around the quality of life data and usually, it is pretty easy to publish 
good quality PRO’s in the journals and there are some journals who really like to have the quality 
of life data of large- scale randomized trials, that are the secondary end points, for example, usually, 
this is highly cited, and so it becomes pretty easy but it depends on the trial and the area, there are 
other areas where there is a lot of clinical interest and then it becomes easy to publish. If it is an 
area where no one is actually interested in and the clinical trial does not actually tell us anything 
then the quality of life data is not interesting either. [040, Journal Editor/Funder/Regulator]
5. Training and guidance
Barriers Supply of PRO expertise I still think there is possibly a lack of expert knowledge around the [UK]…just not enough people; 
we have just had a q- hour meeting with this Neurosurgeon who was embarrassed that he was 
asking me about PRO’s and he has not got a clue…There is still a lack of basic knowledge and 
expert experience, and I still get asked by trial teams, will you please be the PRO expert on our 
trials, you know, I have not got time, but I think, cannot you just do it yourself, it is not that 
difficult, but they clearly do not really know how to do it. [013, Trialist/Chief Investigator]
(Continues)
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underreporting due to possible damage to reputation and lim-
iting future funding prospects. Interviewees also highlighted 
a perceived lack of clarity surrounding PRO analysis meth-
ods as a key barrier. Others felt that a lack of trial resources 
often resulted in the prioritization of the primary outcome at 
the expense of PRO data.
Facilitators to optimal implementation of PRO within tri-
als included: ensuring adequate PRO coverage in the proto-
col to help foster “buy- in” from trial staff; engaging research 
participants by communicating the importance of their PRO 
data; development of a priori plans to minimize avoidable 
missing PRO data by identifying poor PRO compliance in 
real- time, establishing statistical management of missing 
PRO data in advance, and pre- specifying PRO analyses; and 
the use of innovative data- capture technology to reduce bur-
den and increase data quality.
3.3 | Data publication
Discussion focused upon academic publication rather than 
inclusion in regulatory submissions or Health Technology 
Assessment applications. Interviewees highlighted issues 
around selective reporting of PROs, either linked to the 
significance of the primary outcome or of the PRO itself, or 
due to the “lower ranking” of PRO results by trialists. There 
was also a perception that PRO findings were of little inter-
est to journals unless particularly “novel” or “dramatic,” 
and that the inclusion of PRO data alongside the primary 
outcome could be impeded by restrictive word count limits. 
Interviewees discussed solutions including the generation 
of a dissemination plan that includes PROs; encouraging 
Patient and Public Involvement (PPI) throughout the trial 
to foster accountability and promote complete reporting; 
and the availability of the option to include PRO data as 
supplementary files or appendices. When asked about per-
ceived demand for PRO data from journals, participants 
who had successfully led and published research using 
PROs in high- impact journals described how well- written 
papers aimed at appropriate journals would get published. 
Participants, including those employed as journal editors, 
noted that journals are keen to publish high- quality PRO 
data, particularly those from large- scale RCTs, depending 
on the clinical area.
3.4 | Training and guidance
A recurring theme was the perceived difficulty of acquir-
ing and providing PRO training in practice. Respondents 
felt this was due to the lack of awareness of training re-
sources; possible expense; limited time; and particularly 
Study phase and themes Example quote and source identifier and primary stakeholder group
Burden upon researchers I think, as a researcher and especially as a single- handed researcher, that the bureaucracy and the 
paperwork are overwhelming and have become increasingly so over the last ten years. It might 
have modest benefits in some areas but it certainly can hold people back. I think if there is 
guidance, especially if it is mandatory guidance and it is impossible to publish if you do not 
follow that guidance, then you have to really support researchers to access that sort of stuff, 
rather than putting burdens in their way. [020, Trialist/Chief Investigator]
Need for specialized 
training
I do not know if there is a specific training, I think it is just … being very clear, what are the aims 
of your study, are you collecting the outcomes that you need to meet those aims, so I do not 
know whether there is specific training required other than, being trained to put together a 
good research proposal that is going to get funded. [015, Trialist/Chief Investigator]
Facilitators Availability of PRO 
information resources
There is a lot of uncertainty about particularly which primary outcome to pick and which PROs 
are needed but are not going to be overkill and mean that the patients start dropping out of 
the study because they do not want to go through a massive questionnaire booklet. So if the 
training had the right content and … was delivered in a flexible way so that people could easily 
access it, whether that is webinars or what, I do not know, but yes, I could see a role for it. 
[016, Trialist/Chief Investigator]
Integration of guidance I guess by journals insisting on it being done in that way. Most journals insist on the CONSORTs. 
They could also mention CONSORT- PROs then that would a help … I should really know 
more about the fact that the CONSORT has a PRO. I really did not know that. I had heard 
about the other ones. [017. Trialist/Chief Investigator]
Upholding best practices I think it is a multi- stakeholder responsibility … physicians should demand it, clinicians should 
demand it, regulations should demand it, industry themselves should demand it, the payer 
should demand it. I think all of us have a responsibility to ensure that the information that we 
collect during a drug development program is sufficient but also the best it possibly can be to 
determine what the benefits and the risks are [006, Trialist/Chief Investigator]
T A B L E  2  (Continued)
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for generalists, the notion that PROs were one of a mul-
titude of competing for potential training needs, or that 
PROs were not within their remit. However, the majority 
of interviewees felt there was a role for all institutions in-
volved in regulatory, funding, educational, methodological, 
and journalistic activities throughout the research process 
to ensure that PRO training and guidance was available, 
signposted, and readily accessible to stakeholders, with ac-
companying measures to ensure adherence and compliance 
to best practice guidelines.
3.5 | Additional themes
There were two unanticipated themes resulting from the 
interviews (Appendices S3 and S4), drawn from all stake-
holder groups. The first relates to the usefulness of PRO 
data in meeting the information needs of people during di-
agnosis, treatment, and when living with and beyond cancer 
(LWBC). When asked about their experience of accessing 
PRO information, several participants with lived experience 
described how the availability of PRO data during clinical 
decision making would have enabled more informed treat-
ment choices. The second related to the generation of data 
valued by patients through PROs in cancer clinical trials, 
via effective PPI in study question formulation; develop-
ment and use of PRO measures that are relevant and reflect 
patients’ interests; and the simplification of PRO deliv-
ery to minimize patient burden and improve engagement 
(Appendices S3 and S4).
4 |  DISCUSSION
Existing research has drawn valuable insights into the chal-
lenges faced when administering PROs in trials6; however, 
the current study is the first investigation of factors affecting 
PRO trial design, data collection and reporting, or patients’ 
and clinicians’ access to PRO data to inform decision mak-
ing. Our findings highlight a number of potential factors con-
tributing to observed suboptimal PRO protocol quality and 
reporting in cancer clinical trials: low prioritization of PROs; 
lack of training; late inclusion of PROs in trials; uncertainty 
related to analysis; and poor implementation (leading to 
missing data and interpretation issues). These span all phases 
of trial development, implementation, and dissemination and 
require the concerted and coordinated effort by the cancer 
research community to address them, for the benefit of all 
cancer patients. A particular focus should include address-
ing perceptions around the value of PROs and their position 
within the hierarchy of trial outcomes, and adoption of inter-
national guidance around best- practice PRO trial design, data 
capture, analysis, and reporting.
Missing data were a recurring theme and was posited as 
a reason for skepticism around the value of PROs. This is 
reiterated in the literature, where high rates of missing PRO 
data continue to be reported.10 It is hoped that the widespread 
adoption of recent guidance around design and measurement 
selection, implementation, and reporting strategies aimed at 
reducing the instance and impact of missing PRO data will 
support more effective capture of PRO trial data in the fu-
ture.20 Recent international cancer trials have successfully 
collected PRO data on a large scale, while demonstrating 
the ability to do so with very little missing data, minimal re-
source costs, and negligible investigator burden.21 PRO data 
are being successfully collected in challenging trial settings, 
for example, those performed across several centers and in-
cluding highly vulnerable cancer populations.22 The need to 
include patients in the development, application, evaluation, 
and interpretation of PROMs is well established,23 to ensure 
their acceptability and relevance.24
A number of interviewees also supported the a priori 
development of statistical analysis plans including methods 
to address missing PRO data. The imminent publication of 
guidelines arising from the Setting International Standards 
in Analyzing Patient- Reported Outcomes and Quality of Life 
Endpoints (SISAQOL) Data Consortium should help support 
trialists to implement this recommendation.25
There were diverging views around the non- publication of 
PRO data.8,12 While several researchers cited the experience 
of journals’ general reluctance to publish findings, particu-
larly in primary trial manuscripts, interviews with journal ed-
itors suggested the route to publication was influenced instead 
solely by the quality of the individual manuscript. It is difficult 
to reconcile these opposing viewpoints. Open access interna-
tional guidelines are available via the Consolidated Standards 
of Reporting Trials (CONSORT) PRO Extension,26 based on 
the methodological framework for guideline development 
proposed by the Enhancing the Quality and Transparency of 
Health Research (EQUATOR) Network.27 Intended to sup-
port researchers in raising standards of PRO reporting and if 
the broader pool of journal editors share the views of our in-
terviewees, this could increase the probability of publication. 
Recent evidence also suggests an association between im-
proved PRO reporting quality and the quality of the trial pro-
tocol,8 development of which may be aided by the Standard 
Protocol Items: Recommendations for Interventional Trials 
(SPIRIT),28 and the SPIRIT- PRO Extension29 international 
consensus guidelines. Widespread endorsement and adop-
tion of these guidelines by trialists, journals, funders, and 
regulators would help drive up future standards of PRO 
reporting through implementation initiatives such as the 
Patient- Centered Outcomes Research Institute (PCORI) 
funded Patient- Reported Outcomes Tools: Engaging Users 
and Stakeholders (PROTEUS) Consortium.30 Increased in-
terest in PROs is echoed in the work of regulators, such as the 
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Food and Drug Administration (FDA) recent patient- focused 
drug development initiative,31 and the European Medicines 
Agency (EMA) guidance on the use of PROMs in cancer tri-
als.5 Despite this, evidence suggests that the impact of PRO 
data is limited.32,33 Issues relating to PRO- related training 
are identified as a key theme, despite the availability of PRO 
training resources,34– 36 demonstrating the need to enable and 
uphold greater uptake.
In summary, our interviewees suggested future cancer 
trials should include more comprehensive PRO trial design 
and protocol development involving PRO expertise and pa-
tient input, with a focus on standardized administration. They 
also emphasized the need to minimize the burden for patients 
and staff; prevent missing data; address missing data with 
appropriate analysis methods; develop a priori PRO analy-
ses and dissemination plans; and train staff. The use of PPI 
throughout a trial life- cycle was identified as integral to en-
suring PRO data generated through cancer clinical trials are 
relevant and accessible to people with cancer. Unfortunately, 
the study findings suggest that stakeholders perceive and 
observe barriers to the interpretation and dissemination of 
PRO results, and that key factors that arise during the design 
and data collection of cancer clinical trials compromise this 
process.
4.1 | Clinical implications
Our qualitative results suggest that the specific features 
of cancer and treatment affect whether PROs are placed 
lower in the trial outcome hierarchy as compared to sur-
vival outcomes. This appears to shape the expectations of 
those in the field, conceptualizing trials and determining 
research questions, perpetuating the relatively low posi-
tion of PROs in the trial outcome hierarchy. However, the 
interview findings also suggest that the relative position 
of PROs in the cancer trial outcome hierarchy could be 
changing over time. Participants described the growing 
demand for PRO data due to increasing awareness around 
the impact of cancer on individual quality of life and the 
considerable burden associated with the acute, medium- 
term, and late effects of treatment. Participants described 
witnessing relatives and friends undergoing treatment and 
the lasting long- term consequences and how this informed 
the type of information they would seek while considering 
treatments for themselves. This is echoed in studies outlin-
ing the research priorities of those with lived experience 
of cancer,37 reiterating the need to integrate meaningful 
PPI when setting the research agenda. Early and consist-
ent PPI may lead to a shift in emphasis from survival or 
cancer progression in isolation to also include the qual-
ity of survival; patient- centered PRO rationale, aims, and 
objectives; selection of meaningful PROs, thereby making 
subsequent findings potentially more impactful; enhancing 
communication with participants around trial PROs; maxi-
mization of trial feasibility, recruitment, and retention; and 
minimization of PRO burden, participant study drop- out, 
and missing data.20,38– 40
4.2 | Study limitations
The strength of this work lies in the use of rigorous method-
ology; the broad expertise of the interviewees; and the inclu-
sion of numerous stakeholder groups. However, a limitation 
is that international recruitment efforts were focused on the 
PRO and cancer methodology experts rather than across all 
stakeholder groups. A further limitation is that the study was 
at risk of self- selection and social desirability bias, whereby 
participants participated due to a pre- existing interest in 
PROs, portray their behaviors positively due to the nature of 
this study, with increased awareness of methodological is-
sues and need for training. Despite this, the divergence of 
opinions identified indicates that individuals were sampled 
with a wide range of views related to PROs. Another pos-
sible limitation is that through the inclusion of people with 
lived experienced of cancer, there may be a bias toward the 
views of those who have survived and are LWBC. Their per-
spectives are more likely to reflect issues that pertain to the 
long- term impacts of cancer treatments. Similar studies in 
the future may benefit from the inclusion of people affected 
by cancer more broadly, including carers, and those who are 
bereaved.
5 |  CONCLUSIONS
Our aim was to explore with stakeholders the factors influ-
encing suboptimal PRO protocol content, implementation, 
and reporting. These qualitative findings suggest that a lack 
of training, understanding about the value of PRO data (that 
results in low prioritization of PROs in outcome hierarchy), 
difficulties associated with the numerous ways to analyze 
PRO data, and the expertise required to this end can under-
mine their planning, collection, and reporting can undermine 
their planning, collection, and reporting.
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